Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
12:00pm, Tuesday, 05'th Aug 2025
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
11:15am, Tuesday, 05'th Aug 2025
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
10:00am, Tuesday, 05'th Aug 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investor
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
09:53am, Tuesday, 05'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options
GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly
09:09am, Tuesday, 05'th Aug 2025
Novo Nordisk's share price collapse is an overreaction; the market underestimates its robust pipeline and continued double-digit growth potential. The GLP-1 obesity drug market is massive and supports
Novo Resources Releases Updated Corporate Presentation Highlighting Strategic Progress and Growth Initiatives
09:00am, Tuesday, 05'th Aug 2025
PERTH, Western Australia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its update
Nordisk to downgraded by leading investment bank as growth slows and competition intensifies
08:46am, Tuesday, 05'th Aug 2025
UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from DKK600. The downgrade comes after what UBS described as “challenging times”
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
08:45am, Tuesday, 05'th Aug 2025
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
08:35am, Tuesday, 05'th Aug 2025
Novo Nordisk A/V NYSE: NVO stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%.
Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay
05:21am, Tuesday, 05'th Aug 2025
Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A/S (NYSE: NVO) After Class Action Filing
03:43pm, Monday, 04'th Aug 2025
PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
02:55pm, Monday, 04'th Aug 2025
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leadin
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
12:51pm, Monday, 04'th Aug 2025
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
12:51pm, Monday, 04'th Aug 2025
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
